Overview

Tolerance to NeuroEPO in Parkinson Disease

Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
Treatment strategies in Parkinson's disease (PD) can improve a patient's quality of life but cannot stop the progression of PD. The investigators are looking for different alternatives that modify the natural course of the disease and recent research has demonstrated the neuroprotective properties of erythropoietin. In Cuba, the Center for Molecular Immunology (CIM) is a cutting edge scientific center where the recombinant form (EPOrh) and recombinant human erythropoietin with low sialic acid (NeuroEPO) are produced.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
International Center for Neurological Restoration, Cuba
Collaborators:
Center of Molecular Immunology, Cuba
University of Electronic Science and Technology of China